Canada markets closed

Metagenomi, Inc. (MGX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.7000+0.0100 (+0.37%)
At close: 04:00PM EDT
2.9000 +0.20 (+7.41%)
After hours: 07:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.6900
Open2.6900
Bid2.6300 x 100
Ask2.7700 x 100
Day's Range2.6500 - 2.8980
52 Week Range2.6300 - 12.7400
Volume114,321
Avg. Volume98,266
Market Cap101.058M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.0000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
  • GlobeNewswire

    Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months

    Twelve-month durability data from Metagenomi’s ongoing nonhuman primate (NHP) study in hemophilia A remains generally consistent with data previously released at 4.5 months NHPs remain healthy and exhibit normal weight gain; treatment is generally well tolerated Program on track for IND filing in 2026 Company to host conference call with management and Dr. Glenn Pierce, international thought leader in hemophilia A EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: M

  • GlobeNewswire

    Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference

    AI-generated, compact SMART nucleases demonstrated robust genome editing activity in vitro in mammalian cells at multiple therapeutically relevant loci Compact SMART genome editing tools that fit within delivery technologies constrained by cargo size may enable broad disease targeting EMERYVILLE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene edit

  • GlobeNewswire

    Metagenomi to Participate in Upcoming Investor Conferences

    EMERYVILLE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that it will present during the following upcoming investor conferences: Wells Fargo Healthcare Conference, Everett, MassachusettsFireside chat on Wednesday, September 4, 2024, 11:00 AM - 11:35 AM ET with Brian Thomas, CEO, Dr. Sarah Noonberg, CMO, and Alan